Results 121 to 130 of about 7,224 (167)

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living with HIV Aged 50 Years and Older: A Retrospective Analysis of Naïve and Treatment-Experienced Individuals. [PDF]

Viruses
Trizzino M, Pipitò L, Di Figlia F, Bonura S, Zimmerhofer F, Cicero A, Gioè C, Cascio A.   +7 more
europepmc   +1 more source

BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV-Infected Patients. [PDF]

AIDS Res Treat
Pérez-Calvo F, Jover-Diaz F, Delgado-Sánchez E, Peris-García J, Bernabéu-Martínez MÁ.   +4 more
europepmc   +1 more source

Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. [PDF]

Clin Pharmacokinet
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK.   +15 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tenofovir Alafenamide.

The Annals of pharmacotherapy, 2017
To review the pharmacology, efficacy, safety, and place in therapy for tenofovir alafenamide (TAF).A search using PubMed was conducted (2004 to May 2016) using the following keywords: tenofovir alafenamide, TAF, and GS-7340. Articles were evaluated for content, and bibliographies were reviewed.
Amanda K, Gibson, Bhavik M, Shah, Puja H, Nambiar, Jason J, Schafer   +3 more
openaire   +2 more sources

Emtricitabine + tenofovir alafenamide for the treatment of HIV

Expert Opinion on Pharmacotherapy, 2017
Tenofovir alafenamide is a new oral prodrug of tenofovir resulting in relatively low plasma levels and rapid uptake into peripheral blood mononuclear cells in its active form. The United States Food and Drug Administration has now approved this drug coformulated with elvitegravir/cobicistat/emtricitabine, rilpivirine/emtricitabine and emtricitabine ...
Eric Daar
exaly   +3 more sources

Tenofovir alafenamide

Reactions Weekly, 2022
  +4 more sources

Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects

Clinical Pharmacology in Drug Development, 2018
AbstractA fixed‐dose combination of tenofovir alafenamide (TAF) and emtricitabine (FTC) is available in 2 tablet strengths in Japan (FTC/TAF 200/10 mg and FTC/TAF 200/25 mg). These are used once daily in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection.
Hiroyuki, Yamada, Takuma, Yonemura, Takanori, Nemoto, Noriko, Ninomiya, Shin, Irie   +4 more
openaire   +2 more sources